Glaxo Wellcome: top of the class for small molecules; where in genomics?

Abstract

Before its merger, the Glaxo group had a surprisingly small number of patented DNA molecules in its portfolio. This is in contrast to The Wellcome Foundation, which had over 40 patents mainly for the production of reagents for diagnostic kits and also for gene therapy. It is too early to determine the merged Company’s patent strategy in the area of genomics and gene analysis.

• diagnostics
• DNA
• genes
• gene therapy
• Glaxo Wellcome